Serum autoantibody measurement for the detection of hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Middleton, Catrin H ^a   Irving, William ^c   Robertson, John F R ^a   Murray, Andrea ^b   Parsy Kowalska, Celine B ^b   Macdonald, Isabel K ^b   McElveen, Jane ^b   Allen, Jared ^b   Healey, Graham F ^b   Thomson, Brian J ^c   Ryder, Stephen J ^c   Holdenrieder, Stefan ^d   Chapman, Caroline J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Oncimmune Germany GmbH   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; TUMOR MARKER;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPLICATION; EARLY DIAGNOSIS; IMMUNOLOGY; LIVER DISEASE; LIVER NEOPLASMS; MIDDLE AGED; PROCEDURES;

ADULT; AGED; AUTOANTIBODIES; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84905457127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103867     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-917.
2. Cancer Research UK (2010, 19/09/09). "CancerStats." 2010. Available: http://info.cancerresearchuk.org/cancerstats/index.htm.
3. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. (Pubitemid 40372904)
4. Bosch FX, Ribes J, Cleries R, Diaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211.
5. Yi X, Yu S, Bao Y (2013) Alpha-fetoprotein-L3 in hepatocellular carcinoma: A meta-analysis. Clin Chim Acta. 425: 212-220
6. EASL-EORTC (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943.
7. Storr SJ, Chakrabarti J, Barnes A, Murray A, Chapman CJ, et al. (2006) Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther 6: 1215-1223. (Pubitemid 44304689)
8. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, et al. (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18: 868-873. (Pubitemid 47054083)
9. Piura E, Piura B (2011) Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol 2011: 982425.
10. Piura B, Piura E (2009) Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol 2009: 581939.
11. Zayakin P, Ancans G, Silina K, Meistere I, Kalnina Z, et al. (2013) Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer 132: 137-147.
12. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, et al. (2008) Autoantibodies in Lung Cancer - possibilities for early detection and subsequent cure. Thorax 63: 228-233. (Pubitemid 351373718)
13. Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska C, Allen J, et al. (2011) Immuno-biomarkers in small cell lung cancer: Potential early clinical signals. Clin. Cancer Res 17: 1474-1480.
14. Chapman CJ, Healey G, Murray A, Boyle P, Robertson C, et al. (2012) EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol 33: 1319-1326.
15. Shan Q, Lou X, Xiao T, Zhang J, Sun H, et al. (2012) A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett 328: 160-167.
16. Chan CC, Fan CW, Kuo YB, Chen YH, Chang PY, et al. (2010) Multiple serological biomarkers for colorectal cancer detection. Int J Cancer 126: 1683-1690.
17. Li J, Wang LJ, Ying X, Han SX, Bai E, et al. (2012) Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Scand J Immunol 75: 342-349.
18. Kilic A, Schuchert MJ, Luketich JD, Landreneau RJ, Lokshin AE, et al. (2008) Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. J Thorac Cardiovasc Surg 136: 199-204.
19. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, et al. (2006) Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 1: 513-519. (Pubitemid 47181397)
20. Robertson JFR, Chapman CJ, Cheung K-L, Murray A, Pinder SE, et al. (2005) Auto-antibodies in Early Breast Cancer. J Clin Oncol 23: 549.
21. Chapman CJ, Robertson JF, Murray A, Titulaer M, Lang B, et al. (2010) The presence of autoantibodies to tumor-associated antigens can predate clinical diagnosis of small cell lung cancer. Chest 138: 775A.
22. Pedersen JW, Gentry-Maharaj A, Fourkala E-O, Dawnay A, Burnell M, et al. (2013) Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer 108: 107-114.
23. Lu H, Ladd J, Feng Z, Wu M, Goodell V, et al. (2012) Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 5: 1036-1043.
24. Wang K, Xu X, Nie Y, Dai L, Wang P, et al. (2009) Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma. Cancer Lett 281: 144-150.
25. Liu H, Zhang J, Wang S, Pang Z, Wang Z, et al. (2012) Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol 36: 82-88.
26. Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, et al. (2008) Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 7: 4004-4012.
27. Zhang J, Megliorino J, Peng X, Tan E, Chen Y, et al. (2007) Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 46: 107-114. (Pubitemid 44827418)
28. Chen Y, Zhou Y, Qiu S, Wang K, Liu S, et al. (2010) Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett 289: 32-39.
29. Lam S, Boyle P, Healey G, Maddison P, Peek L, et al. (2011) EarlyCDT-Lung: an Immuno-biomarker Test as an Aid to Early Detection of Lung Cancer. Cancer Prev Res 4: 1126-1134.
30. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070-2075. (Pubitemid 38339455)
31. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430 (Pubitemid 32844200)
32. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, et al. (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol;22: 383-389.
33. Murray A, Chapman CJ, Healey GF, Peek LJ, Parsons G, et al.(2010) Technical validation of an autoantibody test for lung cancer. Ann Oncol 21: 1687-1693.
34. Macdonald IK, Allen J, Murray A, Parsy-Kowalska CB, Healey GF, et al. (2012) Development and validation of a high throughput system for discovery of antigens for autoantibody detection. PLoS One 7: e40759.
35. Hollander M, Wolfe DA (1999) Nonparametric Statistical Methods, Second Edition, New York: John Wiley & Sons.
36. Robertson JFR, Graves RL, Price MR, Inventors; Oncimmune Ltd, assignee (2005) Tumour markers. European patent EP-B 1078264.
37. Le Naour F, Brichory F, Misek D, Bréchot C, Hanash S, et al. (2002) A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1: 197-203
38. Dutta J, Fan G, Gelinas C (2008) CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel. J Virol 82: 10792-10802. (Pubitemid 352691189)
39. Bruno S, Savojardo D, Almasio PL, Mondelli MU (2011) Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 3: 21-28.